Advertising Disclaimer
PEDIATRICS Vol. 32 No. 5 November 1963, pp. 880-887
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

VINCRISTINE (LEUROCRISTINE) SULFATE IN THE TREATMENT OF CHILDREN WITH METASTATIC WILMS' TUMOR

Writing Committee

Metastatic Wilms' tumor was temporarily controlled by vincristine (leurocristine) sulfate in 9 of 13 children. The responses to the drug were prompt, becoming apparent within 3 weeks in 75% of the patients. The duration of the responses was relatively short, however, being less than 2 months in half the group. No cross-resistance in antitumor effect with previously administered chemotherapy or radiotherapy was observed.

The vincristine was administered in "priming" doses for 5 days, and thereafter in weekly maintenance doses. Although some of the patients had two or more toxic manifestations, i.e., alopecia, nausea, vomiting, increased irritability, pain in the abdomen and in the jaws, disturbances of gait, and hematuria, only two patients required a temporary alteration of the dosage regimen. No deleterious effects upon the body weight or blood count of any of the patients were detected.

The potential usefulness of vincristine sulfate as a palliative treatment for patients with Wilms' tumor is discussed.

Submitted on March 11, 1963
Accepted on June 15, 1963


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
M. P. Sullivan, W. W. Sutow, A. Cangir, and G. Taylor
Vincristine Sulfate in Management of Wilms' Tumor: Replacement of Preoperative Irradiation by Chemotherapy
JAMA, October 30, 1967; 202(5): 381 - 384.
[Abstract] [PDF]

Home page
 JAMAHome page
D. J. Fernbach and D. T. Martyn
Role of Dactinomycin in the Improved Survival of Children With Wilms' Tumor
JAMA, March 21, 1966; 195(12): 1005 - 1009.
[Abstract] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
J. WINDMILLER CHAIRMAN, D. H. BERRY, T. B. HADDY, T. J. VIETTI, and W. W. SUTOW
Vincristine Sulfate in the Treatment of Neuroblastoma in Children: A Cooperative Study
Arch Pediatr Adolesc Med, January 1, 1966; 111(1): 75 - 78.
[Abstract] [PDF]

Home page
 JAMAHome page
D. H. James Jr., P. George, O. Hustu, E. Wrenn, L. Borella, K. Hernandez, and D. Pinkel
Chemotherapy of Localized Inoperable Malignant Tumors of Children: Preliminary Report
JAMA, August 24, 1964; 189(8): 636 - 638.
[Abstract] [PDF]